FDA removes leash from Verzenio in early breast cancer

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient popula

Routine NHS access to Ibrance assured with new NICE guidance

Thousands of patients with a particular form of breast cancer in England and Wales can be confident they will continue to have access to Pfizer's targeted therapy Ibrance, thanks to new gui

Ibrance trial failure dashes Pfizer’s growth hopes for the d...

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s

NICE backs Ibrance for breast cancer via Cancer Drugs Fund

Scotland backs Pfizer’s Ibrance for breast cancer

Real-world data unlocks Ibrance ok in male breast cancer

The FDA has expanded the use of Pfizer’s Ibrance to include use in breast cancer in men based on a filing that drew heavily on post-marketing and real-world data.